炎症性贫血的治疗进展  

Recent research on the treatment of anemia of inflammation

作　　者：滕广帅[1] 白洁 TENG Guangshuai;BAI Jie(Department of Hematology,The Second Hospital of Tianjin Medical University,Tianjin 300070,China)

机构地区：[1]天津医科大学第二医院血液科,天津300070

出　　处：《天津中医药》2022年第10期1357-1360,共4页Tianjin Journal of Traditional Chinese Medicine

摘　　要：炎症性贫血(AI)发病率高,发病机制复杂。西医治疗的根本在于治疗原发病,补铁和/或应用促红细胞生成刺激剂(ESA)应注意权衡利弊,靶向促炎因子-铁调素-膜铁转运蛋白轴治疗和缺氧诱导因子脯氨酸羟化酶抑制剂(HIF-PHI)作为新型疗法具有广阔前景,中医采用辨证论治、标本兼治的方法治疗AI,优势显著,本文对AI的发病机制及治疗进行综述,以期为中西医结合治疗AI提供依据。The incidence of anemia of inflammation(AI)is high,and the pathogenes is complex.The essence of treating AI is to treat primary diseases.Iron supplement and/or erythropoiesis stimulating agent(ESA)should be applied,and the advantages and disadvantages should be pay attention.Targeted proinflammatory factor ferritin membrane iron transporter axis therapy and hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI)are new therapies for the treatment of AI.The traditional Chinese medicine,which adopting syndrome differentiation and treatment and treating both the primary diseases and the symptoms,plays an important role.This article reviews the pathogenes and the treatment of AI,and with a view to providing references for integrated traditional Chinese and western medicine treatment.

关 键 词：炎症性贫血 铁调素 促红细胞生成素 中医治疗 

分 类 号：R556[医药卫生—血液循环系统疾病]